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Abstract
Background: Leukemia is a heterogeneous disease commonly associated with recurrent chromosomal
translocations that involve tyrosine kinases including BCR-ABL, TEL-PDGFRB and TEL-JAK2. Most studies on the
activated tyrosine kinases have focused on proximal signaling events, but little is known about gene transcription
regulated by these fusions.
Methods: Oligonucleotide microarray was performed to compare mRNA changes attributable to BCR-ABL, TEL-
PDGFRB and TEL-JAK2 after 1 week of activation of each fusion in Ba/F3 cell lines. Imatinib was used to control the
activation of BCR-ABL and TEL-PDGFRB, and TEL-JAK2-mediated gene expression was examined 1 week after Ba/F3-
TEL-JAK2 cells were switched to factor-independent conditions.
Results: Microarray analysis revealed between 800 to 2000 genes induced or suppressed by two-fold or greater by
each tyrosine kinase, with a subset of these genes commonly induced or suppressed among the three fusions.
Validation by Quantitative PCR confirmed that eight genes (Dok2, Mrvi1, Isg20, Id1, gp49b, Cxcl10, Scinderin, and
collagen Va1(Col5a1)) displayed an overlapping regulation among the three tested fusion proteins. Stat1 and Gbp1
were induced uniquely by TEL-PDGFRB.
Conclusions: Our results suggest that BCR-ABL, TEL-PDGFRB and TEL-JAK2 regulate distinct and overlapping gene
transcription profiles. Many of the genes identified are known to be involved in processes associated with
leukemogenesis, including cell migration, proliferation and differentiation. This study offers the basis for further
work that could lead to an understanding of the specificity of diseases caused by these three chromosomal
translocations.
Background
Chromosomal translocations are the most frequently
occurring genetic abnormalities in leukemias and they
exploit a mechanism by which normal regulatory path-
ways are subverted, thereby providing a proliferative
advantage to a leukemic clone. Many of the chromoso-
mal translocations involve tyrosine kinases. In most
cases, translocations juxtapose a tyrosine kinase domain
to another protein containing an oligomerization motif.
For example, BCR-ABL is generated by t(9;22)(q34;q11)
[1], which fuses the N-terminus of BCR to the C-
terminus of ABL. TEL-PDGFRB (t(5;12)(q33;p13)) [2]
and TEL-JAK2 (t(9;12)(p24;p13)) [3,4] fuse the N-termi-
n u so fT E Lt ot h eC - t e r m i n u so fP D G F R Bo rJ A K 2 ,
respectively. In all three fusions, the N-terminal translo-
cation partners contain an oligomerization domain (i.e.
the coiled-coil domain of BCR or the pointed domain of
TEL). The oligomerization domain mediates ligand-
independent activation of the kinase domains, causing
factor-independence in vitro and leukemia-like diseases
in vivo.
The kinase fusions provide a proliferative signal for
the leukemic clone to expand, while additional muta-
tions are necessary to fully elicit the leukemia pheno-
type. For all three fusions, the enhanced proliferative
capacity is associated with activation of STAT proteins
[5-13], various members of MAP kinases [14-18] and
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[23-25]). While BCR-ABL, TEL-PDGFRB and TEL-JAK2
activate overlapping signaling pathways, the relative con-
tribution and requirement for these pathways down-
stream of each fusion is not clear. Given that each of
these pathways can transmit signals to alter gene tran-
scription, it is possible that their signals converge at the
level of gene transcription, resulting in a similar gene
expression pattern. Alternatively, they may result in dis-
tinct gene expression patterns depending on the relative
significance of different pathways downstream of the
three fusions.
The three fusions give rise to distinct diseases accord-
ing to the WHO classification (reviewed in [26]). BCR-
ABL is predominantly described in patients with chronic
myelogenous leukemia (CML). The TEL-PDGFRB trans-
location is commonly associated with chronic myelomo-
nocytic leukemia (CMML), a disease characterized by a
preferential expansion of monocytes [26,27]. TEL-JAK2
has been described in three distinct diseases: pre-B cell
acute lymphoblastic leukemia (ALL), T-cell ALL and
atypical CML. The differences in the clinical features of
the three fusion tyrosine kinases may be, in part, due to
distinct regulation of gene transcription.
In order to investigate this possibility in an unbiased
manner, we used microarray analysis to compare the
effects of BCR-ABL, TEL-PDGFRB and TEL-JAK2 on
gene expression in Ba/F3 cells. We demonstrated that
BCR-ABL, TEL-PDGFRB and TEL-JAK2 elicit distinct
gene expression changes. Notably, TEL-PDGFRB, but
not the other two fusions, induces the expression of
Stat1 and Gbp1. Interestingly, Cd55 and Ndrg1 are
induced by BCR-ABL and suppressed by TEL-PDGFRB,
while Cxcl10 and Scinderin are commonly regulated by
all three fusions. This study illustrates that oncogenic
tyrosine kinases can trigger distinct gene regulation,
which may contribute to specificity downstream of each
fusion protein.
Methods
Cell lines and culture
Ba/F3 cells and Ba/F3 TEL-JAK2(5-19) cells were cul-
tured as previously described [10,16,20]. TEL-JAK2(5-
19) was introduced via electroporation and individual
subclones were isolated by limiting dilution.
Ba/F3 BCR-ABL cells were generated by retroviral
infection of Ba/F3 cells with pMSCV BCR-ABL p210
construct. Ba/F3 TEL-PDGFRB cells were generated by
electroporation. Both cell lines were maintained in
RPMI-complete media supplemented with murine IL-3,
Geneticin and 100 ng/ml of Imatinib. Individual G418-
resistant subclones were isolated by limiting dilution,
and expression of BCR-ABL and TEL-PDGFRB was
confirmed by immunoprecipitation and immunoblot
analysis.
Cell cycle analysis
2×1 0
6 cells were collected, washed once in cold PBS,
fixed in ice-cold 70% ethanol and stored at -20°C. For
propidium iodide staining, cells were washed twice in
cold PBS and incubated in PBS containing RNAse A
(Invitrogen) (1 unit per 10
6 cells) for 30 min at 37°C.
After 30 min, 50 μg/ml of propidium iodide (Roche
Boehringer Mannheim, Laval, QC) was added to the cell
suspension, and cells were analyzed by FACScan. The
cell cycle profile was determined by using the ModFit
LT
® (Verity Software House, Topsham, ME).
Imatinib dose-response assay
Ba/F3 cells stably expressing pMSCV TEL-PDGFRB or
pMIGR BCR-ABL were washed three times in 10 mM
HEPES (pH 7.4)/Hanks balanced salts, and incubated in
RPMI-complete medium for 24 h at 37°C. After 24 h, 2
×1 0
5 cells were resuspended in RPMI-complete media
containing specific amounts of Imatinib mesylate dis-
solved in DMSO. Ba/F3 cells were resuspended in
RPMI-complete media containing 100 pg/ml of IL-3 and
increasing amounts of Imatinib. As a vehicle control,
Ba/F3 were resuspended in RPMI-complete media con-
taining DMSO only.
RNA extraction
Ba/F3 cells were washed three times in 10 mM HEPES
(pH 7.4)/Hanks balanced salts, incubated in RPMI-com-
plete medium for 5 h at 37°C and stimulated with 2 ng/
ml of rmIL-3 for 0, 8, 12, 24 h and 1 week at 37°C.
Ba/F3 BCR-ABL and Ba/F3 TEL-PDGFRB cells were
washed three times and incubated in RPMI-complete
media and Imatinib (1 μg/ml for Ba/F3 BCR-ABL cells
and 100 ng/ml for Ba/F3 TEL-PDGFRB cells) for 5 h at
37°C. After 5 h, cells were washed three times and incu-
bated in RPMI-complete media for 0, 8, 12, 24 h and 1
week at 37°C.
B a / F 3T E L - J A K 2c e l l sw e r ew a s h e dt h r e et i m e sa n d
incubated in RPMI-complete media for 0, 8, 12, 24 h
and 1 week at 37°C.
For all cell lines, cells were harvested at each time-
point for total RNA extraction, which was performed by
using QIAGEN RNAeasy MINI
® (Qiagen, Mississauga,
Ontario, Canada), and the integrity of the RNA samples
was assessed by running a formaldehyde denaturing gel
according to the manufacturer’s protocol.
Oligonucleotide array experiment and data analysis
Further RNA quality assessment, sample RNA in vitro
transcription, labeling and hybridization were conducted
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Children’s Hospital http://www.tcag.ca/ according to the
standard Affymetrix protocols. Hybridization was per-
formed using the Affymetrix mouse MOE430A oligonu-
cleotide array, which represents 13247 unique mouse
gene transcripts. All arrays have been scaled to a target
intensity of 150, and data was analyzed by using Affyme-
trix Micro Array Suite (MAS) 5.0 software to calculate
expression values for each transcript and Detection p-
values. The Detection p-value was calculated by the
Detection algorithm, which assigned a Present (p <
0.04), Marginal (0.04 <p < 0.06) or Absent (0.06 <p) call,
and reflected the confidence of the detection of the
given transcript. All of the reported induced genes dis-
played the Detection score of Present or Marginal at the
1 week point, and all of the reported suppressed genes
displayed the Detection score of Present or Marginal at
the 0 h point. Ratios between the expression levels at
the 0 h and all subsequent time-points were calculated.
For gene expression in Ba/F3 TEL-JAK2 cells, expres-
sion values obtained from Ba/F3 TEL-JAK2 cells at the
1 week time point were compared to the expression
values obtained from Ba/F3 cells at the 0 h time point.
Clustering analysis
Gene expression values were log2 transformed, and two
hundred and fifty of the most highly induced genes and
two hundred and fifty of the most highly suppressed
genes with a Detection score of Present or Marginal at
the 1 week point (for the induced genes) or at the 0 h
point (for the suppressed genes) were selected. Hier-
archical clustering was performed using the Eisen Clus-
ter and TreeView software package using the average
linkage criterion [28].
Validation by quantitative PCR (Q-PCR)
A5μg aliquot of total RNA was reverse transcribed using
Superscript II reverse transcriptase (Invitrogen). A 10 ng
aliquot of cDNA was used for each Q-PCR assay per-
formed with the ABI Prism 7900 HT thermocycler
(Applied Biosystems) using SYBR Green detection (Per-
kin-Elmer Applied Biosystems, Foster City, CA). Each
assay was performed in triplicate using RNA samples
extracted from 2-4 distinct populations of cells. The
sequences of gene transcripts that correspond to the Affy-
metrix probe set were obtained from Genbank accession
numbers listed on the Affymetrix website and primer sets
corresponding to exon sequences for PCR amplifications
were designed using the Primer Express software (Perkin-
Elmer Applied Biosystems, Foster City, CA).
The expression of cyclophilin H was assessed in all
samples, and did not alter significantly at different time-
points, and therefore, was used to normalize starting
cDNA concentrations, and the primers used for all Q-
PCR are listed in Additional file 1: Table S1. Dissocia-
tion curves were performed as routine verification in
order to check the primers for amplification of a single
band, and template dilution standard curves (5-log
range) were conducted with each primer set to verify a
linear relationship between template concentration and
Ct values (R
2 > 0.9). Absolute transcript concentrations
were calculated using standard curves for each primer
set. Relative ratios were then calculated for each cell
type in a manner similar to the microarray ratios in
order to allow relative comparison between data sets.
Antibodies, immunoprecipitation and western blotting
All reagents have been described in earlier publications
[10,16,20].
Ba/F3 BCR-ABL or TEL-PDGFRB cells were washed
three times in 10 mM HEPES (pH 7.4)/Hanks balanced
salts, and resuspended in RPMI-complete media or
RPMI-complete media supplemented with IL-3 ± 1 μg/
ml of Imatinib (Novartis). Lysates were prepared and
analyzed by performing Western blot using the 4G10
anti-phosphotyrosine monoclonal antibody.
Results
BCR-ABL, TEL-PDGFRB and TEL-JAK2 trigger distinct gene
expression changes at steady state
We examined changes in gene expression triggered by
IL-3-stimulation and activation of BCR-ABL, TEL-
PDGFRB or TEL-JAK2 at steady-state levels by using
the MOE430A Affymetrix oligonucleotide array. In
order to attribute changes in gene expression directly to
BCR-ABL and TEL-PDGFRB kinase activity, we used
Imatinib mesylate, which inhibits ABL, PDGFRB and
the c-kit receptor (reviewed in [29] and [30]). Since Ba/
F3 cells do not rely on ABL, PDGFRB or c-kit for their
growth or survival, we reasoned that Imatinib would not
interfere with the normal signaling pathways of Ba/F3
cells and that we could use this agent in order to regu-
late the activation of BCR-ABL and TEL-PDGFRB.
Ba/F3 cells were incubated in the absence of IL-3 for 5
h. Ba/F3 cells expressing BCR-ABL or TEL-PDGFRB
were incubated without IL-3 and with Imatinib for 5 h.
Previously, we observed that cells are arrested at the
G0/G1 phase of the cell cycle with this treatment, and
could be stimulated to enter the cell cycle by IL-3 or by
kinase activation (Additional file 2: Figure S1 and Addi-
tional File 3: Figure S2).
After 5 h of incubation, Ba/F3, Ba/F3 BCR-ABL and
Ba/F3 TEL-PDGFRB cells were activated. Total RNA
was isolated from each cell line at 0, 8, 12, 24 h and 1
week. Total RNA was also isolated from Ba/F3 TEL-
JAK2 cells that had been washed and incubated in IL-3-
free media for 1 week to achieve steady-state factor-
independence.
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Imatinib, there is no inhibitor that can be used to speci-
fically inhibit TEL-JAK2 without perturbing the normal
growth and survival of Ba/F3 cells. Because Ba/F3 cells
are IL-3-dependent and thus require Jak2, any conven-
tional Jak2 inhibitor would disturb the normal growth
and survival of Ba/F3 cells. To circumvent this issue, we
compared the gene expression profile 1 week after Ba/
F3 TEL-JAK2 cells were switched to factor-indepen-
dence to the gene expression in Ba/F3 cells that had
been depleted of cytokine for 5 h.
As we were mainly interested in the genes that are
regulated at steady state, we identified genes that were
induced or repressed by 2-fold or greater after 1 week.
For the induced genes, we selected those genes that
showed a Detection call of Present (p-value < 0.04) or
Marginal (0.04 <p-value < 0.06) at the 1-week point. For
the repressed genes, we selected those genes that
showed a Detection call of Present or Marginal at the 0
h point.
Using these criteria, all three fusion kinases induced
distinct gene expression changes when compared to IL-
3 at steady-state (Figure 1A). Similarly, when the fusion
proteins were compared amongst themselves, the three
fusion kinases induced distinct gene expression changes
(Figure 1B). Downstream of each kinase fusion, we iden-
tified a subset of genes that are regulated by one fusion
kinase but not by the other two kinases, as well as genes
that are commonly regulated by all three fusions.
Next, 500 genes were selected that were most highly
induced or suppressed at steady state (250 induced and
250 suppressed genes) in cells expressing BCR-ABL or
TEL-PDGFRB fusion protein. They were then clustered
based on the changes in their gene expression at 8, 12,
and 24 h time-points, using the Eisen hierarchical clus-
tering algorithm (Figure 2). For each fusion kinase,
genes were segregated into two main clusters that con-
sisted of induced genes and suppressed genes. Within
each cluster, we observed that a subset of genes dis-
played changes during the first 24 h of activation ("Early
Genes”), while others displayed changes after 24 h of
activation ("Late Genes”). Selected genes were validated
by Q-PCR at one or more time-points (Figure 2, high-
lighted in red or green).
i) Genes regulated by BCR-ABL
Among the 543 genes induced or suppressed by BCR-
ABL at steady state by two-fold or more, but not by
TEL-PDGFRB or TEL-JAK2, four highly induced genes
Cd55, Dok2, Mrvi1, and N-myc down-regulated gene-1
(Ndrg1) were selected for validation and were confirmed
to be significantly induced (Table 1). Interestingly, Q-
PCR validation/experiments suggests Dok2 and Mrvi1
were induced by TEL-PDGFRB, although both genes
were initially identified to be uniquely induced by BCR-
ABL in microarray experiments (see summary in Table
5). Moreover, Cd55 and Ndrg1 were confirmed to be
suppressed by TEL-PDGFRB (see summary in Table 5).
ii) Genes regulated by TEL-PDGFRB
G e n e st h a ta r er e g u l a t e db yT E L - P D G F R B ,b u tn o tb y
BCR-ABL or TEL-JAK2, are identified (Table 2). Inter-
estingly, a large number of these genes have been pre-
viously reported to be IFN-stimulated genes (ISG) such
as Cxcl10, Gbp1, Isg20, Stat1, Irf1 and Irf7 [33]. A sub-
set of these genes (Vegf, Pim1 and Isg20) was also
induced upon IL-3 stimulation and all three tyrosine
kinases, suggesting that these targets may be bona fide
cytokine-regulated transcripts. However, TEL-PDGFRB
stimulated the expression of 25 ISGs (summarized in
Table 3). Among the TEL-PDGFRB-regulated genes,
Cxcl10, Gbp1 and Stat1 were selected for validation by
Q-PCR.
iii) Genes regulated by TEL-JAK2
Genes regulated by TEL-JAK2 at 1 week, but not by
BCR-ABL or TEL-PDGFRB, were identified and the
abridged list is shown in Table 4. Of these, Cited2 and
Bnip3 were found in our previous cDNA microarray
analysis to be suppressed during the first 12 h after Ba/
F3 TEL-JAK2 cells are switched to factor-independence
(data not shown). Findings from the present study
demonstrate that these transcripts may remain sup-
pressed at steady state.
iv) Genes commonly regulated by BCR-ABL, TEL-PDGFRB
and TEL-JAK2
Finally, we identified a subset of genes that were regu-
lated by all three fusion kinases. Id1, gp49b, Col5a1,
Scinderin and Isg20 were selected for validation by Q-
PCR (Figures 3 &4). Among the five transcripts, only
Scinderin was commonly suppressed by all three fusions
in the Q-PCR analysis, while the other four transcripts
displayed overlapping regulation between two of the
three fusion kinases (Table 5).
v) BCR-ABL triggers early gene expression changes of
Scinderin and Id1
We examined the kinetics of the regulation of a subset
of transcripts (Id1, Scinderin, Stat1, Col5a1, Cxcl10 and
gp49b) that had been confirmed by Q-PCR to be signifi-
cantly regulated by BCR-ABL or TEL-PDGFRB fusion
protein after 1 week. As we have no means to inhibit
TEL-JAK2-mediated proliferation, the analysis of the
kinetics was performed only in Ba/F3 cells and Ba/F3
cells expressing BCR-ABL or TEL-PDGFRB.
After 0, 8, 12, and 24 h of kinase activation, total RNA
was collected and Q-PCR was performed. Despite the
large variance between replicate experiments, we consis-
tently observed that the BCR-ABL-mediated induction
of Id1 transcript occurs within the first 8 h after BCR-
ABL activation in Ba/F3 BCR-ABL cells (Figure 5). We
also assessed the changes in the Id1 transcript level
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Figure 1 Comparison of gene expression profiles among BCR-ABL, TEL-PDGFRB, TEL-JAK2 and IL-3. Ba/F3 cells were washed and
incubated in IL-3-depleted media for 5 h, then stimulated with IL-3 for 0 h or 1 week. Ba/F3 BCR-ABL cells and Ba/F3 TEL-PDGFRB cells washed
and incubated in the media depleted of IL-3 and supplemented with Imatinib for 5 h, were washed and incubated in the absence of IL-3 and
Imatinib for 0 h or 1 week. Ba/F3 TEL-JAK2 cells were washed and incubated in IL-3-depleted media for 1 week. Total RNA was collected at 0 h
and 1 week time-points, and was used for microarray analysis. For all cell lines except for Ba/F3 TEL-JAK2 cells, changes in gene expression were
calculated using the expression values at 1 week and the 0 h within each cell type. For Ba/F3 TEL-JAK2 cells, expression values obtained from
Ba/F3 TEL-JAK2 cells at the 1 week time-point were compared to the expression values obtained from Ba/F3 cells at the 0 h time-point. The
number of genes that were induced or suppressed by 2-fold or more with significant detection scores in each cell type as well as in overlapped
regions is indicated in the Venn diagrams.
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Figure 2 Comparative gene expression profiling between genes regulated by BCR-ABL and genes regulated by TEL-PDGFRB.B a / F 3
BCR-ABL cells and Ba/F3 TEL-PDGFRB cells were washed and incubated in media depleted of IL-3 and supplemented with Imatinib for 5 h. Cells
were washed and incubated in the absence of IL-3 and Imatinib to activate the fusion kinases for 0, 8, 12, 24 h and 1 week. Total RNA was
collected at each time-point and was used for microarray analysis. The 250 most highly induced and the 250 most highly suppressed genes at 1
week were identified in cells with BCR-ABL (Top) or TEL-PDGFRB (Bottom) fusion proteins. The 500 genes induced or suppressed by each fusion
protein were hierarchically clustered using the Eisen Cluster and Tree View programs and are displayed on a log2 color scale, with red
representing induced genes and green representing suppressed genes. Grey represents omitted data. Shown in the second and the third
columns are the examples of genes that are regulated by 2-fold or greater within 24 h of activation ("Early Genes”), and after 24 h ("Late Genes”).
Genes that were validated by Q-PCR are highlighted in red (induced) or green (suppressed) in the gene list.
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Although a trend of gene induction was observed during
the first 24 h, this trend was highly variable, and we
were unable to detect a consistent induction at early
time-points downstream of TEL-PDGFRB (data not
shown).
In contrast to Id1, the gp49b transcript did not display
any significant change downstream of BCR-ABL during
the first 24 h (Figure 5 & data not shown). Similarly, the
expression of Cxcl10 did not change substantially down-
stream of BCR-ABL or TEL-PDGFRB even though it is
induced by all three fusions kinases at steady state
(Table 5 & data not shown).
Among the suppressed genes, Scinderin was signifi-
cantly suppressed by all three fusions and the suppres-
sion occurred within the 24 h of activation of BCR-ABL
or TEL-PDGFRB (Figure 5 & data not shown). Finally,
Col5a1 did not exhibit any significant change at the ear-
lier time-points downstream of BCR-ABL or TEL-
PDGFRB (Figure 5 & data not shown).
Temporal regulation of Stat1 was also assessed down-
stream of TEL-PDGFRB, and it was not significantly
altered at the earlier time-points (data not shown).
Discussion and conclusions
BCR-ABL, TEL-PDGFRB and TEL-JAK2 are recurrent
chromosomal translocations associated with distinct
forms of leukemia that differ in the target cell and in
disease aggressiveness. All three fusion proteins activate
similar signaling pathways involving MAP kinases, Stat
proteins and PI3K in hematopoietic cell lines. Our cur-
rent understanding of the cytosolic signaling pathways
Table 1 Genes regulated by BCR-ABL.
A. Microarray Analysis
Genes Regulated by BCR-ABL
Fold-Change Gene Name
Induced Genes 13.00 Complement component 3 (C3)
12.12 Murine retrovirus integration site 1 (Mrvi1)*
11.31 CD55 antigen (CD55)*
4.29 N-myc downstream regulated gene 1 (Ndrg1)*
3.48 Downstream of Tyrosine kinase 2 (Dok2)
2.64 CCAAT enhancer binding protein, beta (Cebpb)
2.46 A disintegrin and metalloprotease domain 8 (Adam8)
2.46 Arrestin, beta 2 (Arrb2)
2.40 Selectin, lymphocyte (Sell)
2.30 Talin (Tln)
2.30 Enolase 3, beta muscle (Eno3)
Suppressed Genes 3.03 Interleukin-15 (Il15)
3.03 Neuronal pentraxin receptor (Nptxr)
3.03 Ciliary neurotrophic factor (Cntf)
2.64 Vimentin (Vmn)
2.46 Suppression of tumorigenicity 7 (St7)
2.30 Nuclear factor IX (Nfix)
2.30 Growth arrest specific 5 (Gas5)
2.14 Ribosomal protein S20 (Rps20)
B. Validation by Quantitative PCR
Gene Name Mean Fold-Change p-Value
Cd55 4.87 ± 1.31 0.02
Dok2 4.57 ± 1.82 0.07
Mrvi1 11.08 ± 0.76 0.0001
Ndrg1 4.92 ± 0.50 0.01
(A) Selected genes induced or suppressed by BCR-ABL by two-fold or more after 1 week of activation. Genes chosen for validation by Q-PCR are denoted by
asterisks. (B) Q-PCR was performed in triplicate using RNA samples extracted from 2-4 distinct cell populations Mean fold-induction at 1 week compared to the
expression at 0 h and standard error mean (SEM) are shown for each gene. A student t-test was performed to obtain P-values for the difference between the
mean gene expression level at 0 h and 1 week. “I” and “S” denote “induced” and “suppressed”, respectively
Although not selected for the validation study, Talin was previously reported to be induced in a BCR-ABL expressing cell line [31,32].
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for these differences, and we reasoned that examination
of gene expression changes regulated by the three
fusions might provide insights in this regard.
The results from the oligonucleotide array analysis
demonstrate that the three tyrosine kinase fusions trig-
g e rb o t ho v e r l a p p i n ga n dd i s t i n c tg e n ee x p r e s s i o n
changes, and these results were confirmed by Q-PCR
(Table 5). In addition, we demonstrated that TEL-
PDGFRB induced a large number of ISG.
B e c a u s ew ec a na t t r i b u t eg e n ee x p r e s s i o nc h a n g e s
downstream of BCR-ABL and TEL-PDGFRB directly to
these kinases, we chose 12 genes regulated by BCR-ABL
or TEL-PDGFRB for Q-PCR validation based on the
fold-change in their expression, the Detection score in
the gene expression as predicted by MAS 5.0, and their
cellular function. As we were interested in the genes
that could potentially contribute to leukemogenesis, we
selected those that modulate cell proliferation and
differentiation.
Validation by Q-PCR revealed that Dok2, Isg20, Id1,
Mrvi1, gp49b, Cxcl10, Scinderin and Col5a1 display an
overlapping regulation among the three fusion kinases
by 2-fold or greater at steady-state (Table 5). In particu-
lar, Cxcl10 and Scinderin are commonly regulated by all
three fusions. Cd55 and Ndrg1 are suppressed by TEL-
PDGFRB, whereas they are induced by BCR-ABL.
Finally, Stat1 and Gbp1 are uniquely induced by TEL-
PDGFRB.
Most studies that examine the gene expression
changes associated with BCR-ABL have compared the
normal hematopoietic progenitors to the CML progeni-
tors [32,34-38]. A caveat of this approach is that it is
difficult to attribute genetic changes directly to BCR-
ABL as they may have arisen from secondary mutations.
The use of Imatinib allowed us to link changes in gene
expression directly to BCR-ABL and TEL-PDGFRB, and
to examine the kinetics of gene regulation. Kinetic ana-
lysis revealed that a distinct subset of genes was regu-
lated within the first 8 h of kinase activation (e.g. Id1,
Scinderin), while others were regulated after 24 h (e.g.
Stat1, Cxcl10, gp49b and Col5a1). The late changes in
the expression of genes such as Stat1, Cxcl10, gp49b
and Col5a1 may be attributable to the relatively small
extent of changes in gene expression at the earlier time-
points, and it is possible that early changes occurred but
were not detectable in our system.
Many of the genes identified in our study are asso-
ciated with regulation of cell migration, proliferation
and differentiation, all of which are known to be per-
turbed during leukemogenesis. Considering the func-
tions of the validated genes, the finding that these genes
are regulated downstream of the three fusions suggest
that they may play important roles during leukemia
development.
Cxcl10, gp49b and Mrvi1 are membrane proteins up-
regulated in our experiments. Cxcl10, is a member of
the chemokine family, that plays an important role in
regulating movement and retention of hematopoietic
progenitor cells within the bone marrow microenviron-
ment. Chemokines have been implicated in Imatinib
resistance [39] and as a potential mechanism for effec-
tive interferon treatment [40]. CML cells fail to respond
to at least two different chemokines: macrophage
inflammatory protein (MIP)-1a and stromal-derived fac-
tor (SDF)-1 [41-44]. Moreover, it was demonstrated that
BCR-ABL both positively and negatively regulates SDF-
1-mediated signaling suggesting that BCR-ABL autono-
mously regulates the cell migration and retention of
hematopoietic progenitors in the marrow [43,45].
gp49b, also known as leukocyte immunoglobulin-like
receptor, subfamily B, member 4 (Lilrb4), is a ITIM-
containing, Ig-like receptor expressed on mast cells that
plays an inhibitory role in IgE- or cytokine-dependent
mast cell activation and inflammation [46-48]. gp49b
was found to be up-regulated at the mRNA level by G-
CSF stimulation in multiple myeloid cell lines [49] and
its related member, LILRB3 has been reported to be
highly induced in CML-chronic phase samples in micro-
array experiments [32]. While we observed a transient
induction of gp49b around the 8 h time-point in some
instances (Figure 5), this transient induction was not
sustained at 24 h. Given that gp49b is significantly
Table 5 Summary of genes regulated by IL-3, BCR-ABL,
TEL-PDGFRB and TEL-JAK2 at steady-state (1 week).
Gene Name IL-3 BCR-ABL TEL-PDGFRB TEL-JAK2
Dok2 - Up* - -
Daf1 - Up Down -
Ndrg1 - Up Down -
Stat1 - - Up -
Gbp1 - - Up ?
Isg20 - - Up Up
Id1 Up* Up Up* -
Mrvi1 -U p U p -
Gp49b Up Up* - Up
Cxcl10 -U p U p U p
Scin - Down Down Down
Col5a1 Down Down Down* -
All genes were validated by Q-PCR using RNA samples extracted from 2-5
distinct cell populations. Data represent mean fold-change in gene expression
at 1 week compared to the expression at 0 h and SEM. All changes in gene
expression were associated with p-value < 0.05 as determined by a student t-
test unless indicated by asterisk, which denotes p-value < 0.1. Dotted line (-)
indicates no significant change
In addition, Cxcl10 was confirmed to be induced by all three fusions even
though it was initially identified as a TEL-PDGFRB-regulated gene (Tables 2 &
5).
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Page 8 of 16elevated at 1 week, our findings suggest that the induc-
tion of gp49b may be subsequent to changes that occur
early in response to BCR-ABL activation.
Col5a1 is a member of Type V collagen family, which
mediates cell adhesion by binding preferentially to a2b1
integrin [50]. Although no direct evidence exists
between Type V collagens and leukemia, adhesion
receptors play a critical role during hematopoiesis as
they relay the external cues to the cells, and CML cells
are defective in cell adhesion to the bone marrow
stroma and extracellular matrix. Moreover, Col1a1 and
Col4a4, have been previously reported to be highly sup-
pressed in CML chronic phase samples in cDNA micro-
array experiments [32,51-56]. Col5a1 is a HIF-1a target
gene, and the expression of HIF-1a has been shown to
be a positive prognostic factor in lymphoma [57]. In our
study, Col5a1 was significantly suppressed at steady
state by both BCR-ABL and TEL-PDGFRB, suggesting
that its suppression may contribute to leukemia caused
by these two fusions.
Several signal transducers were regulated by activated
tyrosine kinases in our experiments including Dok2 and
Scinderin. Dok2 was consistently elevated downstream
of BCR-ABL and TEL-PDGFRB. Dok1 and Dok2 exhibit
increased tyrosine phosphorylation in p210
BCR-ABL-
expressing cell lines [58] and tyrosine phosphorylation
of Dok2 was significantly down regulated in Mo7e/
p210
BCR-ABL cells treated with Imatinib [59]. Dok2 med-
iates cytoskeletal activity by its direct interaction with c-
Abl, resulting in increased c-Abl tyrosine phosphoryla-
tion and kinase activity [60]. In contrast to our study,
Nowicki et al. observed a strong down-regulation of the
Dok2 transcript in the bone marrow cells of patients
with CML at blast crisis [32]. The study by Nowicki et
al., however, has a few caveats, which may explain the
discrepancy between our results. Firstly, the finding was
made by cDNA microarray analysis, and the result was
not validated by a quantitative assay. Secondly, the
authors compared a highly heterogeneous population of
CML samples from peripheral blood mononuclear cells
Table 2 Genes regulated by TEL-PDGFRB.
A. Microarray Analysis
Genes Regulated by TEL-PDGFRB
Fold-Change Gene Name
Induced Genes 234.50 Chemokine (C-X-C motif) ligand 10 (Cxcl10)
103.12 Guanylate nucleotide binding protein 1 (Gbp1)
64.00 Immune responsive gene 1 (Irg1)
42.22 Ubiquitin specific protease 18 (Usp18)
19.00 Signal transducer & activator of transcription 1 (Stat1)
14.55 Interferon regulatory factor 7 (Irf7)
7.46 Leukemia inhibitory factor (Lif)
6.96 Jun oncogene (Jun)
5.84 Vascular endothelial growth factor A (Vegfa)
Suppressed Genes 2.83 Gelsolin (Gsn)
2.64 Elk3, member of Ets oncogene family (Elk3)
2.64 Cyclin I (Ccni)
2.64 Cyclin-dependent kinase inhibitor 2c (Cdkn2c)
2.46 Leukotriene A4 hydrolase (Lta4h)
2.46 Adducin 1, alpha (Add1)
2.46 Neutrophilic granule protein (Ngp)
2.46 Eukaryotic elongation factor-2 kinase (Eef2k)
2.46 EGF-like module containing, mucin-like, hormone receptor-like sequence 1 (Emr1)
B. Validation by Quantitative PCR
Gene Name Mean Fold-Change p-Value
Cxcl10 61.55 ± 20.98 0.02
Stat1 2.70 ± 0.45 0.009
Gbp1 83.47 ± 20.89 0.008
(A) Selected genes that were induced or suppressed by TEL-PDGFRB by two-fold or more after 1 week of activation. Genes chosen for validation by Q-PCR are
denoted by asterisk. (B) Q-PCR was performed in triplicate using RNA samples extracted from 4-5 distinct cell populations. Mean fold-induction at 1 week
compared to the expression at 0 h, and SEM are shown for each gene. A student t-test was performed to obtain p-values for the difference between the mean
gene expression level at 0 h and 1 week
Kim et al. BMC Cancer 2011, 11:528
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hand, the discrepancy between these reports may reflect
differences in the experimental systems employed in
each of these studies. In addition, two studies demon-
strated that a compound Dok1/Dok2 knockout mouse
developed a CML-like disease [61,62]. We observed no
difference in Dok1 expression in Ba/F3 BCR-ABL cells
in our microarray experiments. Additionally, the role of
Dok2 downstream of TEL-PDGFRB remains to be
explored.
Scinderin (adseverin) was highly suppressed by all
three fusions at steady state, and this occurred as early
as 8 h after BCR-ABL or TEL-PDGFRB activation. Scin-
derin is a Ca
2+-dependent actin severing protein,
expressed in normal megakaryocytes and platelets that
controls actin filament length [63]. The role of Scinderin
is crucial in regulating cortical F-actin to mediate secre-
tion including the release of platelets from mature
megakaryocytes. Proteomic analysis of Ba/F3 BCR-ABL
and Ba/F3 TEL-PDGFRB cells revealed that Scinderin is
down-regulated by BCR-ABL, but not by TEL-PDGFRB,
however, the result was not validated by Western blot-
ting [64]. Expression of Scinderin in MEG-01 cells pro-
moted platelet formation and inhibited tumor formation
when MEG-01/Scinderin cells were injected into nude
mice. MEG-01 is a CML cell line, however, the role of
scinderin in BCR-ABL function was not examined in
this study [65]. Nevertheless, our results lead to the
hypothesis that suppression of scinderin may represent
a mechanism by which BCR-ABL, TEL-PDGFRB and
TEL-JAK2 promote leukemic transformation.
ID1, (Inhibitor of DNA binding 1), has been pre-
viously shown to be induced in samples from CML
patients in chronic phase of the disease suggesting its
potential role in leukemia development, and our data
further support this hypothesis [32]. Another study con-
firmed that Id1 was up-regulated in response to various
oncogenic tyrosine kinases, including BCR-ABL, TEL-
Table 3 Induction of Interferon-Stimulated Genes downstream of TEL-PDGFRB.
Gene Description Fold-induction
Chemokine (C-X-C motif) ligand 10 (Cxcl10) 234.5
Guanylate nucleotide binding protein 1 (Gbp1) 103.1
Guanylate nucleotide binding protein 2 (Gbp2) 53.0
Signal transducer and activator of transcription 1 (Stat1) 19.0
Interferon-regulatory factor 7 (Irf7) 14.6
Myxovirus-resistance 1 (Mx1) 10.1
Isg15 ubiquitin-like modifier (Isg15) 8.2
HLA, Class I, G (Hla-g) 7.2
Proteasome subunit, beta type 9 (Psmb9) 6.3
Proteasome subunit, beta type 10 (Psmb10) 5.7
Lectin, galactoside-binding, soluble, 3 binding protein (Lgals3bp) 4.6
Caspase 4 (Casp4) 4.4
Interferon-induced protein with tetratricopeptide repeats 2 (Ifit2) 4.3
Nicotinamide phosphoribosyltransferase (Nampt) 4.3
Interferon-regulatory factor 1 (Irf1) 4.2
Tyrosyl tRNA synthetase (Yars) 4.1
Tripartite motif containing 21 3.7
N-myc and Stat interactor (Nmi) 3.3
Pml transcription factor (Pml) 3.1
Tryptophanyl tRNA synthetase (Wars) 2.8
Eif2 alpha kinase 3 (Eif2ak3) 2.6
Proteasome subunit, beta type 8 (Psmb8) 2.4
Proteasome 28 subunit, alpha (Psme1) 2.3
Interferon regulatory factor 9 (Irf9) 2.2
Protein phosphatase 5, catalytic subunit (Ppp5c) 2.2
Genes regulated by TEL-PDGFRB that were previously reported to be ISGs were identified. Data represent the fold-changes in gene expression at steady state
obtained from the microarray experiment
All three genes were induced by TEL-PDGFRB as confirmed by Q-PCR (Table 2). Interestingly, the expression of Cxcl10 was similarly elevated downstream of BCR-
ABL, whereas the induction of Stat1 and Gbp1 was observed uniquely downstream of TEL-PDGFRB (see summary in Table five).
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ITD [66]. Moreover, inhibition of each of those kinases
in leukemic cell lines resulted in significant reductions
in Id1 expression, suggesting that Id1 is a common
downstream target of deregulated kinases. Id proteins
are dominant negative regulators of Helix-loop-helix
transcription factors that govern growth and develop-
ment in mammals [67]. Previously, it has been shown
that Id1 can be regulated by C/EBPb [68], and we
detected an elevated level of the Cebpb transcript 1
week after BCR-ABL activation. Other immediate early
gene(s) may be involved in mediating the observed
induction of Id1.
Finally, Stat1 and Gbp1 were uniquely induced by TEL-
PDGFRB. Tyrosine phosphorylation of Stat1 and DNA
binding has been previously observed downstream of
BCR-ABL [5,7], TEL-PDGFRB [11] and TEL-JAK2 [10].
Interestingly, the induction of Stat1 occurred relatively late
(after 24 h) in response to TEL-PDGFRB activation. Given
that TEL-PDGFRB also induced a large number of IFN-
regulated genes including Gbp1, it is tempting to speculate
that there may exist an autocrine loop of IFN-g, and that
this in turn induces the transcription of Stat1 and Gbp1.
In support of this hypothesis, Ohmine et al. reported the
elevated levels of transcription of IFN-related genes
including IFN-g and IFN-g receptor two in CML cells
from patients in the chronic phase [34]. Moreover, Advani
et al. observed that transcription of a group of IFN-induci-
ble genes was significantly increased in primary mouse
bone marrow cells expressing p185 BCR-ABL compared
to those expressing p210 BCR-ABL, and this was accom-
panied by an induction of IFN-g [36]. However, neither
IFN-g nor its receptors were induced at any of the time
points examined in our experiments. It will be interesting
to determine whether Stat1 exerts a direct transcriptional
effect in TEL-PDGFRB transformed cells, independent of
IFN-g. In terms of its role during leukemogenesis, how-
ever, Stat1 was shown to be dispensable in a myeloproli-
ferative disease induced by Tel-PDGFRB [69].
In summary, our study revealed that BCR-ABL, TEL-
PDGFRB and TEL-JAK2 trigger distinct, yet overlapping
changes in gene expression. Several genes that are
known to be involved in regulating cell migration, pro-
liferation and differentiation were significantly induced
or suppressed at steady state as determined by Q-PCR,
giving rise to a hypothesis that their regulation
Table 4 Genes regulated by TEL-JAK2 at steady state.
Microarray Analysis
Genes Regulated by TEL-JAK2
Fold-Change Gene Name
Induced Genes 3.90 0-6-methylguanine-DNA methyltransferase (Mgmt)
3.20 Serum deprivation response (Sdpr)
3.18 Growth arrest specific 5 (Gas5)
3.13 Immediate early response 2 (Ier2)
2.74 Cbp/p300 interacting transactivator 2 (Cited2)
2.69 E2f transcription factor 6 (E2f6)
2.38 Pannexin 1 (Panx1)
2.17 Myosin VIIa (Myo7a)
2.12 Tnf receptor-associate factor 5 (Traf5)
2.12 Cyclin-dependent kinase inhibitor 2a (Cdkn2a)
2.00 Rab33b, member of Ras oncogene family (Rab33b)
Suppressed Genes 6.81 Chemokine (C-C) receptor 1 (Ccr1)
3.30 Apoptosis inhibitory protein 5 (Api5)
2.98 Bcl2 adenovirus E1b 19 kDa interacting protein 3-like (Bnip3)
2.85 Runt-related transcription factor 1 (Runx1)
2.68 Lim only 4 (Lmo4)
2.61 Chemokine (CXC motif) ligand 13 (Cxcl13)
2.47 Axin1 (Axin1)
2.17 Rho family GTPase RhoA (RhoA)
2.12 Chemokine (C-C motif) receptor 1 (Ccr1)
Ba/F3 cells were washed and incubated in IL-3-depleted media for 5 h and total RNA was collected as reference RNA. Ba/F3 TEL-JAK2 cells were washed three
times and incubated in IL-3-depleted media for 1 week and total RNA was collected. Microarray analysis was performed and changes in the gene expression
between the reference RNA and the RNA collected from Ba/F3 TEL-JAK2 cells were calculated. Genes that are induced or suppressed by two fold or greater were
identified.
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Figure 3 A subset of genes is commonly induced by BCR-ABL, TEL-PDGFRB and TEL-JAK2. Ba/F3 BCR-ABL cells and Ba/F3 TEL-PDGFRB
cells were washed and incubated in the media depleted of IL-3 and supplemented with Imatinib for 5 h. Cells were washed and incubated in
the absence of IL-3 and Imatinib to activate the fusion kinases for 0 h and 1 week. Ba/F3 TEL-JAK2 cells were washed and incubated in IL-3-
depleted media for 1 week, and Ba/F3 cells were washed and incubated in IL-3-depleted media for 5 h to be used as a reference for Ba/F3 TEL-
JAK2 cells. Total RNA was collected from each cell line and microarray analysis was performed using a mouse oligonucleotide array. For cells
expressing BCR-ABL or TEL-PDGFRB, changes in gene expression were calculated using the expression values at 1 week and 0 h. For Ba/F3 TEL-
JAK2 cells, expression values obtained from Ba/F3 TEL-JAK2 cells at the 1-week time point were compared to the expression values obtained
from Ba/F3 cells after 5 h of IL3-depletion. Fold-inductions of gene expression are indicated in the table (Bottom) and are displayed in a bar-
graph (Top). Asterisks denotes genes that were validated by Q-PCR. Phlda1, Pleckstrin homology-like domain, family A, member 1; Pdxl,
podocalyxin; Dusp6, dual specificity phosphatase 6; Ifi47, interferon gamma inducible protein, 47 kDa; Il4ra, interleukin 4 receptor, alpha; Tcrg-
V4, T-cell receptor gamma, variable 4; Pim1, proviral integration site 1; Cish, cytokine inducible SH2-containing protein; Isg20, interferon
stimulated protein 20; gp49b, C3H gp49b; Spred1, Sprouty protein with EVH-1 domain 1, related sequence; Id1, transcription factor Id1; Atf4,
activating transcription factor 4; Siah2, Seven in absentia 2; Serpinb1a, serine(or cysteine) proteinase inhibitor, clade B (ovalbumin) 1a.
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Figure 4 A subset of genes is commonly suppressed by BCR-ABL, TEL-PDGFRB and TEL-JAK2. Genes induced or suppressed by BCR-ABL,
TEL-PDGFRB and TEL-JAK2 by 2-fold or greater were identified. Fold-suppressions of gene expression are indicated in the table (Bottom) and are
displayed in a bar-graph (Top). Asterisks denote genes that were validated by Q-PCR. Pdcd4, programmed cell death 4; Gadd45a, growth arrest
and DNA-damage-inducible 45a; Col5a1, procollagen, type V, alpha1; Lamb1, laminin B1 subunit; Myb, myeloblastosis oncogene; Pik3c2g, PI3-
kinase, C2 domain containing gamma polypeptide; Hdac7, histone deacetylase 7; Cyp26a1, Cytochrome P450, family 26, subfamily a,
polypeptide 1; H2bfs, H2B histone family, member 2; Ttyh2, tweety homolog 2; Scin, scinderin.
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Page 13 of 16downstream of the three fusions may contribute to leu-
kemogenesis. Further characterization of the genes iden-
tified in our study may enhance our understanding of
the molecular basis underlying the specificity of diseases
caused by the three fusion proteins.
Additional material
Additional file 1: Table S1. Primer sequences used for Q-PCR.
Additional file 2: Figure S1. Imatinib inhibits kinase activities of BCR-
ABL and TEL-PDGFRB. Ba/F3 cells expressing BCR-ABL (A) or TEL-PDGFRB
(B) were washed and incubated in the presence of IL-3 and Imatinib
(blue), or in the absence of IL-3 and in the presence of Imatinib (red) for
48 h. The X-axes represent a range of Imatinib concentrations tested. The
green lines represent a vehicle control where cells were incubated in the
absence of IL-3 and increasing amounts of DMSO, which was used to
dissolve Imatinib. The arrows indicate the doses selected for culturing
Ba/F3 cells expressing BCR-ABL or TEL-PDGFRB C, D; Lysates were
collected in an IL-3-dependent state (IL3+/Imat+) and factor-independent
state (IL3-/Imat-) and Western blotting was performed using an anti-
phosphotyrosine monoclonal antibody to detect phosphorylated forms
of BCR-ABL (C). Phosphorylated TEL-PDGFRB was detected by
immunoprecipitation with a Tel-antibody, followed by Western blotting
using 4 G10 (D). For IL-3-dependent state, Ba/F3 TEL-PDGFRB cells and
Ba/F3 BCR-ABL cells were incubated in the presence of 0.1 or 1 mg/ml
of Imatinib, respectively.
Additional file 3: Figure S2. Cell cycle changes induced by BCR-ABL,
TEL-PDGFRB and IL-3. Ba/F3, Ba/F3 BCR-ABL and Ba/F3 TEL-PDGFRB cells
growing in RPMI and IL-3 were washed. Ba/F3 cells were resuspended in
RPMI complete media and Ba/F3 BCR-ABL and Ba/F3 TEL-PDGFRB cells
were resuspended in RPMI complete + Imatinib for 5 h to induce cell
cycle arrest. Ba/F3 cells were stimulated with IL-3 for the indicated
lengths of time. Cells expressing BCR-ABL or TEL-PDGFRB were washed
to remove Imatinib, and incubated in RPMI media depleted of IL-3 and
Imatinib in order to activate BCR-ABL and TEL-PDGFRB for the indicated
lengths of time. Cells were harvested at each time-point and analyzed
for changes in the G0/G1 fraction and the S fraction. Results are
representative of data obtained from three independent experiments.
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Figure 5 Regulation of Id1, Scinderin, Gp49b and Col5a1 by BCR-ABL. Total RNA was extracted at 0, 8, 12, and 24 h after BCR-ABL
activation in Ba/F3 BCR-ABL cells. Q-PCR was performed and relative gene expression was calculated with respect to the expression level at 0 h.
Line graphs represent mean fold-changes and SEM in the gene expression obtained from four separate experiments. The student t-test was
performed to identify statistically significant changes at 95% (*) or 90% (**) confidence level.
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